Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Ulcerative Colitis (UC), Crohn Disease (CD)
Interventions: APP, CBT, HELP, PEER; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ulcerative Colitis
Interventions: Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg, Placebo, Asacol® 400 mg; Procedure · Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 76
States / cities: Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more

Conditions: Wounds and Injuries
Interventions: Allevyn Life, Foam dressing with an integrated adhesive border; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Tustin, California • Wichita, Kansas • McAllen, Texas

Conditions: Venous Leg Ulcer
Interventions: GrafixPL, Control; Other
Lead sponsor: Osiris Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Doral, Florida • Weymouth, Massachusetts

Conditions: Esophagitis, Reflux, Esophagitis, Peptic
Interventions: Dexlansoprazole MR, Lansoprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 2,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 100
States / cities: Anniston, Alabama • Hueytown, Alabama • Huntsville, Alabama + 97 more

Conditions: Pyoderma Gangrenosum
Interventions: Spesolimab, Placebo matching to spesolimab, Prednisone, Prednisolone; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 23 more

Conditions: Neuropathic Diabetic Ulcer - Foot
Interventions: Integra® Dermal Regeneration Template, Conventional Wound Therapy; Device · Other
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 32
States / cities: Mobile, Alabama • Bakersfield, California • Castro Valley, California + 27 more

Conditions: Ulcerative Colitis
Interventions: PF-06651600 or Placebo, PF-06700841 or Placebo, PF-06700841, PF-06651600; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 60
States / cities: Dothan, Alabama • Long Beach, California • Los Angeles, California + 26 more

Conditions: Erosive Esophagitis, Reflux Esophagitis, GERD
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Inflammatory Bowel Disease, Ulcerative Colitis
Interventions: Balsalazide Disodium; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 95
States / cities: Birmingham, Alabama • Tempe, Arizona • Fayetteville, Arkansas + 82 more

Conditions: Impaired Wound Healing, Venous Insufficiency of Leg, Diabetic Ulcers
Interventions: Harvesting Device (CelluTome©); Device
Lead sponsor: SerenaGroup, Inc.; Network
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 18
States / cities: Boca Raton, Florida • Homestead, Florida • Largo, Florida + 15 more

Conditions: Systemic Sclerosis
Interventions: treprostinil diethanolamine; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 19 more

Conditions: Chronic Skin Ulcers
Interventions: Contact ultrasonic debridement device; Device
Lead sponsor: Calvary Hospital, Bronx, NY; Other
Eligibility: 18 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Neuroendocrine Tumors
Interventions: Capecitabine, Temozolomide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Ulcerative Colitis
Interventions: NX-13 250mg, NX-13 750mg, NX-13 Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Miami, Florida • Orlando, Florida • Tampa, Florida + 8 more

Conditions: Ulcerative Colitis (UC), Inflammatory Bowel Disease
Interventions: Infliximab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Ulcerative Colitis
Interventions: ABX464, Placebo; Drug
Lead sponsor: Abivax S.A.; Industry
Eligibility: 16 Years and older
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 46
States / cities: Birmingham, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 39 more

Conditions: Diabetic Foot Ulcers, Pressure Ulcers
Interventions: HP828-101, Hydrogel/Hydrocolloid; Device
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 11
States / cities: Bakersfield, California • Chula Vista, California • Fresno, California + 7 more

Conditions: Diabetic Ulcer of Plantar Aspect of Left Foot, Diabetic Ulcer of Plantar Aspect of Right Foot, Diabetic Polyneuropathy
Interventions: nerve decompression; Procedure
Lead sponsor: Association of Extremity Nerve Surgeons; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 6
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 3 more

Conditions: Gastrointestinal Disease, Inflammatory Bowel Diseases
Interventions: HealthVoyager, Standard Practice; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 25 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Pressure Ulcers
Interventions: DynaSense sensor; Device
Lead sponsor: Leaf Healthcare, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Inflammatory Bowel Diseases, Insomnia
Interventions: Cognitive Behavioral Therapy for Insomnia (CBT-I); Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: Not listed
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Diabetic Foot Ulcer, Surgical Wound
Interventions: Natrox® Oxygen Wound Therapy; Device
Lead sponsor: Inotec AMD Limited; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Los Angeles, California • Miami, Florida • Miami Lakes, Florida + 15 more

Search by objective public record fields.

Exploring Multiple Self-Help Interventions to Promote Self-Efficacy and Overcome Disability

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

Managing Wounds With Allevyn Life in a Home Health Care Environment

Study to Evaluate Safety and Efficacy of GrafixPL for the Treatment of Venous Leg Ulcers

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

A Safety and Efficacy Study of INTEGRA® Dermal Regeneration Template for the Treatment of Diabetic Foot Ulcers

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis

Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study

Clinical Trial to Evaluate Blister Graft Utilizing a Novel Harvesting Device for Treatment of Venous Leg Ulcers

Open-Label Study of Oral Treprostinil in Digital Ulcers

Ultrasonic Wound Debridement vs. Standard Sharp Debridement

Capecitabine and Temozolomide for Neuroendocrine Cancers

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

Early Serum Infliximab Levels in Severe Ulcerative Colitis.

ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Evaluation of the Effects of HP828-101 Versus Standard of Care in the Management of Partial or Full Thickness Wounds

Nerve Decompression for Ulcer Recurrence Avoidance (DURA)

Using Virtual Reality for Patients With Gastrointestinal Disease

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

A Pilot Study to Assess the DynaSense System

Feasibility of Insomnia Tracking and Treatment in IBD

The Effect of Natrox® Oxygen Wound Therapy on the Healing Rate of Chronic Diabetic Foot Ulcers